Dosimetric predictors of symptomatic radiation necrosis after five-fraction radiosurgery for brain metastases. (March 2021)

• Record Type: Journal Article
• Authors: Andruska, Neal; Kennedy, William R.; Bonestroo, Liberty; Anderson, Rebecca; Huang, Yi; Robinson, Clifford G.; Abraham, Christopher; Tsien, Christina; Knutson, Nels; Rich, Keith M.; Spencer, Christopher; Huang, Jiayi
• Is Part Of: Radiotherapy and oncology. Volume 156(2021)
• Page Start: 181
• Page End: 187
• Publication Date: 2021-03
• Subjects: Brain metastases -- Radiation necrosis -- Stereotactic radiosurgery -- Fractionated radiosurgery; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.12.011
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Radiation necrosis (RN) is the dose-limiting side-effect of 5-fraction SRS (5fSRS). The 2-year cumulative incidence of symptomatic RN (sRN) after 5fSRS was 14%. The incidence of sRN is significantly higher in lesion treated with prior SRS. BrainV25 and BrainV30 are strong predictors of sRN for 5fSRS. Exceeding BrainV25 > 16 cm 3 or BrainV30 > 10 cm 3 significantly increases sRN risk. Abstract: Background: To identify factors predictive of developing symptomatic radiation necrosis (sRN) among patients with either intact or resected brain metastases undergoing five-fraction stereotactic radiosurgery (5fSRS). Methods: Multi-institutional retrospective review of 117 brain metastases from 83 patients treated with 5fSRS. The cumulative incidence of sRN and predictors of sRN were calculated using Gray's competing risks and Cox regression. Results: The median dose of 5fSRS was 30 Gy (range: 25–40), and 21 lesions (18%) had prior SRS. After a median follow-up of 10.3 months (range: 3–52), the cumulative sRN incidence was 15%, with a median time to sRN of 6.9 months (range: 1.8–31.7). sRN incidence was significantly higher among the lesions treated with prior SRS: hazard ratio (HR): 7.48 [95% confidence interval: 2.57–21.8]. Among lesions without prior SRS, higher volume of uninvolved brain receiving 25 Gy (BrainV25; HR: 1.07 [1.02–1.12]) and 30 Gy (BrainV30; HR: 1.07 [1.01–1.33]) were the most significant factors associated with sRN. Similar results were also observed among the patients with prior SRS. For lesions without prior SRS, BrainV25 > 16 cm 3 (HR: 11.7 [1.47–93.3]) and BrainV30 > 10 cm 3 (HR: 7.08 [1.52–33.0]) were associated with significantly higher risk of sRN. At two years, the sRN incidence was 21% if violating either dosimetric threshold and 2% if violating neither ( p = .007). Conclusion: BrainV25 and BrainV30 are significant dosimetric predictors of sRN of brain metastases treated with 5fSRS. In the absence of prior SRS, maintaining BrainV25Gy < 16 cm 3 and BrainV30Gy < 10 cm 3 may minimize sRN risk.